"Side effects--part of the package": a mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India.
Adult
Antitubercular Agents
/ adverse effects
Delivery of Health Care
Female
Follow-Up Studies
Health Personnel
/ psychology
Humans
Incidence
India
/ epidemiology
Male
Middle Aged
Mycobacterium tuberculosis
/ drug effects
Patients
/ psychology
Referral and Consultation
Retrospective Studies
Surveys and Questionnaires
Treatment Outcome
Tuberculosis, Multidrug-Resistant
/ drug therapy
Young Adult
Adverse drug event
Drug resistant tuberculosis
Incidence
India
Operational research
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
02 Dec 2020
02 Dec 2020
Historique:
received:
30
01
2020
accepted:
24
11
2020
entrez:
3
12
2020
pubmed:
4
12
2020
medline:
15
12
2020
Statut:
epublish
Résumé
High rates of Adverse Events (AEs) during treatment is one of the leading causes of unsuccessful treatment outcomes among patients with drug resistant tuberculosis (DR-TB). However, information related to AEs is not systematically collected and managed under programmatic setting. The present study assessed the a) incidence and pattern of adverse events in first three months of DR-TB treatment initiation; b) treatment seeking behaviour for AE management; and c) explore the challenges in seeking treatment and reporting AEs. This mixed methods study included all patients diagnosed and initiated on treatment under RNTCP during July-September 2018 at Ahmedabad DR-TB centre. The patients were interviewed telephonically and assessed for all AEs experienced by them. In-depth interviews and key-informant interviews were conducted among patients, DOTS supervisors and programme staff (treatment supervisors, medical officer and district program managers). Total 207 AEs were reported by the 74 DR-TB patients. All patients experienced at least one AE during initial treatment period. Incidence rate of AEs (experienced) was 3.11 (1st month-4.6, 2nd month-2.7, 3rd month-2.02) per 100 person days. Of the 207 AEs, gastro-intestinal (59, 28.3%), ophthalmic (32, 15.4%) and otolaryngology (25, 11.9%) system related AEs were commonly experienced. Treatment was not sought in two-fifths of the AEs. Themes and sub-themes related to challenges in treatment seeking or reporting of AEs were 1) Patient related-Misconceptions, accessibility and affordability of management, lack of counselling support, stigma and discrimination, and past treatment experience; 2) Health system related- lack of guidelines and training for AE management, 3) Poor coordination between hospital and tuberculosis centre. The incidence of AEs was high among patients with DR-TB in the first three months of treatment and treatment seeking/reporting was low. Adequate health education and counselling of the patient and orientation of the health systems is the need of the hour. An efficient real-time reporting and management of AE should be developed and tested for effective DR-TB control.
Sections du résumé
BACKGROUND
BACKGROUND
High rates of Adverse Events (AEs) during treatment is one of the leading causes of unsuccessful treatment outcomes among patients with drug resistant tuberculosis (DR-TB). However, information related to AEs is not systematically collected and managed under programmatic setting. The present study assessed the a) incidence and pattern of adverse events in first three months of DR-TB treatment initiation; b) treatment seeking behaviour for AE management; and c) explore the challenges in seeking treatment and reporting AEs.
METHODS
METHODS
This mixed methods study included all patients diagnosed and initiated on treatment under RNTCP during July-September 2018 at Ahmedabad DR-TB centre. The patients were interviewed telephonically and assessed for all AEs experienced by them. In-depth interviews and key-informant interviews were conducted among patients, DOTS supervisors and programme staff (treatment supervisors, medical officer and district program managers).
RESULTS
RESULTS
Total 207 AEs were reported by the 74 DR-TB patients. All patients experienced at least one AE during initial treatment period. Incidence rate of AEs (experienced) was 3.11 (1st month-4.6, 2nd month-2.7, 3rd month-2.02) per 100 person days. Of the 207 AEs, gastro-intestinal (59, 28.3%), ophthalmic (32, 15.4%) and otolaryngology (25, 11.9%) system related AEs were commonly experienced. Treatment was not sought in two-fifths of the AEs. Themes and sub-themes related to challenges in treatment seeking or reporting of AEs were 1) Patient related-Misconceptions, accessibility and affordability of management, lack of counselling support, stigma and discrimination, and past treatment experience; 2) Health system related- lack of guidelines and training for AE management, 3) Poor coordination between hospital and tuberculosis centre.
CONCLUSION
CONCLUSIONS
The incidence of AEs was high among patients with DR-TB in the first three months of treatment and treatment seeking/reporting was low. Adequate health education and counselling of the patient and orientation of the health systems is the need of the hour. An efficient real-time reporting and management of AE should be developed and tested for effective DR-TB control.
Identifiants
pubmed: 33267826
doi: 10.1186/s12879-020-05660-w
pii: 10.1186/s12879-020-05660-w
pmc: PMC7709264
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
918Références
J Glob Infect Dis. 2018 Jul-Sep;10(3):119-120
pubmed: 30166808
Mediterr J Hematol Infect Dis. 2014 Sep 01;6(1):e2014061
pubmed: 25237474
BMC Health Serv Res. 2008 Apr 16;8:85
pubmed: 18416841
PLoS One. 2016 Mar 09;11(3):e0150849
pubmed: 26959366
Wiley Interdiscip Rev Syst Biol Med. 2011 Mar-Apr;3(2):129-35
pubmed: 20803507
BMC Fam Pract. 2008 Jan 03;9:1
pubmed: 18173835
J Clin Diagn Res. 2015 Oct;9(10):FC01-4
pubmed: 26557538
Public Health Action. 2017 Jun 21;7(2):116-122
pubmed: 28695084
J Nat Sci Biol Med. 2013 Jan;4(1):191-6
pubmed: 23633861
Lung India. 2017 Nov-Dec;34(6):522-526
pubmed: 29098997
PLoS One. 2015 Aug 24;10(8):e0135802
pubmed: 26301748
J Infect Dev Ctries. 2015 Aug 29;9(8):821-8
pubmed: 26322873
Int J Tuberc Lung Dis. 2016 Apr;20(4):442-7
pubmed: 26970151
BMC Med Res Methodol. 2013 Nov 14;13:140
pubmed: 24229315
BMC Res Notes. 2015 Dec 22;8:809
pubmed: 26695761
Saudi Pharm J. 2014 Apr;22(2):163-9
pubmed: 24648829
Int J Public Health. 2008;53(1):3-4
pubmed: 18522360
J Infect Public Health. 2016 Jul-Aug;9(4):478-84
pubmed: 26724262
Infect Dis Poverty. 2018 Jan 12;7(1):3
pubmed: 29325589
Am J Manag Care. 2008 Aug;14(8):530-9
pubmed: 18690769
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
PLoS One. 2013 Jun 04;8(6):e65037
pubmed: 23750225
J Eval Clin Pract. 2015 Apr;21(2):339-46
pubmed: 25645368
Br J Clin Pharmacol. 1995 Mar;39(3):223-6
pubmed: 7619660
Sultan Qaboos Univ Med J. 2015 May;15(2):e250-6
pubmed: 26052459
PLoS One. 2012;7(7):e40781
pubmed: 22792406
PLoS One. 2015 Mar 17;10(3):e0120161
pubmed: 25781958